Triple-leveraged ETFs aren’t for everyone, but if you believe biotech is about to break out, Direxion Daily S&P Biotech Bull ...
MRNA shares rise after upbeat 2025 sales, stronger cash outlook and detailed 2026 guidance, alongside multiple pipeline ...
We came across a bearish thesis on Alexandria Real Estate Equities, Inc. on Compounding Dividends’s Substack by TJ ...
SAN FRANCISCO — Despite all the hopeful chatter about the life sciences industry making a rebound after a multiyear ...
Expects 2025 revenue of approximately $1.9 billion (unaudited), $100 million above midpoint communicated on 3Q25 ...
The company recently hit significant roadblocks with its BTK inhibitor, but there are plenty of fish in the sea for the drug ...
In a new letter, Noubar Afeyan, Ph.D., co-founder of Moderna and CEO of Flagship Pioneering, warns that these actions risk undermining the foundations of science itself to the ultimate detriment of ...
Parabilis Medicines raised $305 million in a Series F round led by RA Capital, Fidelity and Janus Henderson, with crossover ...
Stéphane Bancel, CEO of vaccine maker Moderna, addressed shareholders in a letter that dissected the events of 2025 while ...
11d
Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine
Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010 CAMBRIDGE, MA / ACCESS Newswire / January 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today provided an ...
The U.S. Food and Drug Administration (FDA) is considering adding the strongest safety warning available to COVID-19 vaccines. The move has alarmed many outside health experts, who say there is no ...
The U.S. Food and Drug Administration is reportedly weighing whether it will place a “black box” warning label on COVID vaccines, according to CNN, despite research and real-world data demonstrating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback